Advertisement
Home Tags Pembrolizumab

Tag: pembrolizumab

ESMO 2020: First-in-class MK-4830 Antibody Targeting ILT4 Shows Promising Preliminary...

Editorial Team -
Merck | MSD Exhibition booth at the 2019 annual meeting of the American Society of Medical Oncology (ASCO).

Pembrolizumab Approved for Treatment Advanced Cutaneous Squamous Cell Carcinoma

Peter Hofland, Ph.D -
Seattle Genetics. Exhibition booth during the 2019 annual meeting of the American Society of Medical Oncology (ASCO). In the back of the booth the enfortumab vedotin presentation.

Potential Accelerated Approval Enfortumab Vedotin + Pembrolizumab in Metastatic Urothelial Cancer

Peter Hofland, Ph.D -

Combination Enfortumab Vedotin + Pembrolizumab Granted Breakthrough Therapy in Bladder Cancer

Peter Hofland, Ph.D -

Enfortumab Vedotin + Pembrolizumab Shrink Tumors in the Majority of Bladder...

Peter Hofland, Ph.D -
Doctor discussing treatment options with a patient.

FDA Approves Novel Treatments for Metastatic Urothelial Cancer – But More...

Andrea Maddox-Smith -

Enfortumab Vedotin + Pembrolizumab to be Evaluated in Metastatic Bladder Cancer

Peter Hofland, Ph.D -
Glioblastoma with extreme nuclear enlargement.

Tasadenoturev + Pembrolizumab Shows Clinical Benefit in Recurrent Glioblastoma

Peter Hofland, Ph.D -
Woman with lung cancer during medical visit

WCLC 2019: Updates from the Pembrolizumab Clinical Development Program

Peter Hofland, Ph.D -
Human kidney cross section. Photo courtesy: 2019 Fotolia

Europe Adopts Pembrolizumab + Axitinib as First-Line Treatment for Advanced Renal...

Peter Hofland, Ph.D -
123Page 1 of 3

LATEST NEWS

© 2001 - 2020 Sunvalley Communication, LLC. All Rights Reserved.